Search IconSearch

Tag: ASCO2023

23-CNR-3898261-CQD-Hero-650×450 Dr Gupta
July 10, 2023/Cancer/Research

Enfortumab Plus Pembrolizumab May Represent New First-Line Standard in Advanced Urothelial Cancer

Potential treatment option for patients who are ineligible for cisplatin

23-CNR-3898264-CQD-Hero-650×450 Stevenson
June 15, 2023/Cancer/Research

Population-Based Analysis Highlights Disparities in Lung Cancer Mortality in U.S.

Targeted interventions may prove beneficial for vulnerable subgroups, researchers suggest

23-CNR-3898263-CQD-Hero-650×450 Gerds
June 13, 2023/Cancer/Research

Luspatercept Shows Promise as Treatment for Anemia in Patients With Myelofibrosis

Approach resulted in transfusion independence and durable anemia response

outreach to underserved communities
June 2, 2023/Cancer/News & Insight

Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

ASCO 2023
May 18, 2023/Cancer/Research

10 ASCO Presentations You Don’t Want to Miss

Emerging research and innovation shared

BackPage 1 of 1Next